POMDOCTOR Ltd has announced a significant change in its corporate structure by terminating its American Depositary Receipt (ADR) program. This decision, approved by the company's board on September 3, 2026, and shareholders on September 30, 2026, allows the company to directly list its Class A ordinary shares on Nasdaq. This strategic move is expected to enhance POMDOCTOR's market presence and streamline its operations.
As part of the transition, the ADR program and the related deposit agreement will terminate prior to the market opening on October 21, 2026. At this time, the American Depositary Shares (ADSs) will be mandatorily canceled and exchanged for Class A ordinary shares, a process referred to as the Mandatory Exchange.
Alongside the termination of the ADR program, POMDOCTOR will execute a share consolidation. This consolidation will convert every ten ordinary shares of each class into one ordinary share of the same class. Consequently, holders of ten ADSs will receive three post-consolidation Class A ordinary shares. The shares are expected to begin trading under the symbol "POM" on Nasdaq with a new CUSIP number.
The company has also appointed TranShare Corporation as its transfer agent in the United States for the Class A ordinary shares. This change is part of POMDOCTOR's efforts to enhance its operational efficiency and shareholder value.
Founded in Guangzhou, POMDOCTOR operates in the miscellaneous retail sector, as classified under the SIC code 5900. The company's decision to terminate its ADR program and list directly on Nasdaq is indicative of a broader trend in the retail industry, where companies are seeking more direct engagement with investors and a clearer market presence.
Details were not available in the SEC filing regarding the next steps beyond the planned listing on October 21, 2026.